{
    "organizations": [],
    "uuid": "eccdcdd78fb39e14c0f274e1d8df744b5788d009",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-paratek-pharmaceuticals-reports-q4/brief-paratek-pharmaceuticals-reports-q4-loss-per-share-0-78-idUSASB0C89L",
    "ord_in_thread": 0,
    "title": "Paratek Pharmaceuticals Reports Q4 Loss Per Share $0.78",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 1 (Reuters) - Paratek Pharmaceuticals Inc:\n* PARATEK PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND REMAINS ON TRACK FOR COMMERCIAL LAUNCH BY FIRST QUARTER 2019\n* Q4 LOSS PER SHARE $0.78 * Q4 EARNINGS PER SHARE VIEW $-0.75 — THOMSON REUTERS I/B/E/S\n* AS OF DECEMBER 31, 2017, PARATEK HAD CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $151.7 MILLION‍​ Source text for Eikon: (Reuters.Brief@thomsonreuters.com)\n ",
    "published": "2018-03-01T20:17:00.000+02:00",
    "crawled": "2018-03-02T20:16:05.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "paratek",
        "pharmaceutical",
        "inc",
        "paratek",
        "pharmaceutical",
        "report",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "remains",
        "track",
        "commercial",
        "launch",
        "first",
        "quarter",
        "q4",
        "loss",
        "per",
        "share",
        "q4",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "december",
        "paratek",
        "cash",
        "cash",
        "equivalent",
        "marketable",
        "security",
        "source",
        "text",
        "eikon"
    ]
}